Amyloidosis treatment depends entirely on which type you have, because each type involves a different misfolded protein and requires a different strategy. The three most common forms are AL (light chain), ATTR (transthyretin), and AA (secondary) amyloidosis, and all three now have treatments that can slow progression, protect organs, and significantly extend survival. Five-year survival for AL amyloidosis, the most aggressive form, has climbed from 15% in the 1980s to 45% in the 2010s, largely due to newer drug combinations.
AL Amyloidosis: Targeting Abnormal Plasma Cells
AL amyloidosis is caused by abnormal plasma cells in the bone marrow that produce misfolded light chain proteins. These proteins deposit in organs like the heart, kidneys, and liver, gradually impairing their function. Treatment works by eliminating the rogue plasma cells so they stop producing the toxic protein.
The current first-line therapy combines four drugs: daratumumab (a targeted antibody that locks onto plasma cells), bortezomib, cyclophosphamide, and dexamethasone. This regimen, often abbreviated Dara-VCd, represents a major leap forward. The goal is to achieve at least a very good partial response, meaning the abnormal light chains in your blood drop to near-normal levels. If this depth of response isn’t reached with the initial regimen, doctors have several next steps available, including stem cell transplantation, pomalidomide-based therapy, or other drug combinations.
Stem Cell Transplant
Autologous stem cell transplant remains one of the most effective treatments for eligible patients. It involves collecting your own stem cells, using high-dose chemotherapy to wipe out the diseased bone marrow, then reinfusing the stem cells to rebuild it. Not everyone qualifies, though. Eligibility depends on how well your heart and kidneys are functioning. Key thresholds include adequate kidney filtration (creatinine clearance above 50 mL/min) and cardiac biomarkers below certain cutoffs that indicate the heart hasn’t sustained too much damage. Patients with advanced heart involvement from amyloid deposits are generally steered toward drug-only regimens instead, since the transplant procedure carries higher risk when the heart is compromised.
ATTR Amyloidosis: Stabilizers and Gene Silencing
ATTR amyloidosis involves the transthyretin protein, which normally carries thyroid hormone and vitamin A through the bloodstream. When this protein becomes unstable, it breaks apart and forms amyloid deposits, most often in the heart and nerves. ATTR comes in two forms: hereditary (caused by a gene mutation) and wild-type (age-related, typically affecting men over 70). Both are now treatable.
TTR Stabilizers
Tafamidis works by binding to the transthyretin protein and holding it in its normal shape, preventing it from breaking apart and forming amyloid. It’s taken as a daily pill and is approved for ATTR cardiomyopathy, the form that stiffens the heart. Clinical trials have shown it reduces hospitalizations and improves survival compared to placebo. For many patients with ATTR heart disease, tafamidis is the foundation of treatment.
Gene Silencing Therapies
A newer class of drugs works by shutting down production of the transthyretin protein altogether. These RNA interference therapies instruct liver cells to stop making TTR, dramatically lowering the amount of protein available to misfold. Patisiran is given as an intravenous infusion every three weeks, while vutrisiran is a subcutaneous injection every three months. Both were studied primarily in hereditary ATTR with nerve damage and showed meaningful improvement in neuropathy scores. The less frequent dosing schedule of vutrisiran makes it more convenient for long-term use.
Gene Editing
A CRISPR-based therapy called NTLA-2001 takes a more permanent approach. Rather than temporarily silencing the TTR gene, it edits the gene directly in liver cells. In early clinical trials, a single intravenous infusion reduced blood levels of transthyretin by more than 90% within 28 days, and those reductions held through four to six months of follow-up. Side effects were minimal: two of twelve patients experienced a temporary infusion reaction, one of which was more significant but resolved without lasting effects. No other treatment-related adverse events or worrisome lab changes were reported. If longer-term data holds up, this could eventually mean a one-time treatment instead of lifelong medication.
AA Amyloidosis: Controlling the Source
AA amyloidosis is fundamentally different from the other types because it’s driven by chronic inflammation. Conditions like rheumatoid arthritis, inflammatory bowel disease, and certain inherited fever syndromes cause the liver to continuously produce an inflammatory protein called SAA. When SAA levels stay elevated for years, the protein can misfold and deposit in organs, especially the kidneys.
Treatment centers on aggressively controlling the underlying inflammatory disease to bring SAA levels back into the normal range. This is genuinely life-saving. For patients with autoimmune or autoinflammatory conditions, biologic therapies that block specific inflammatory signals have become the mainstay. Anti-TNF drugs have been credited with reducing the incidence of AA amyloidosis in patients with chronic arthritis over the past decade. For conditions driven by a different inflammatory pathway, drugs that block the IL-1 signaling system have shown striking results, including marked improvement in kidney function and reduction of protein loss in the urine. The principle is the same regardless of which biologic is used: monitor SAA levels closely and tailor treatment to keep them as low as possible.
Managing Organ Damage
Regardless of type, amyloidosis often requires supportive treatment for the organs already affected. The heart and kidneys bear the brunt in most cases, and managing their symptoms is just as important as targeting the underlying protein.
Heart Involvement
Amyloid deposits stiffen the heart walls, making it harder for the chambers to fill with blood. This leads to fluid retention, shortness of breath, and fatigue. Volume management is central to treatment. Loop diuretics are the cornerstone, helping your body shed excess fluid and relieve congestion. Mineralocorticoid receptor antagonists are often added. Thiazide diuretics are used cautiously because they carry a higher risk of overdoing it, potentially causing dangerous drops in potassium or worsening kidney function.
A common complication is orthostatic hypotension, where your blood pressure drops sharply when you stand up, causing dizziness or fainting. This happens because amyloid deposits damage the autonomic nerves that regulate blood pressure. Peripheral vasoconstrictors like midodrine can help support blood pressure while still allowing diuretics to do their job. Many standard heart failure drugs, including certain beta-blockers and ACE inhibitors, are poorly tolerated in amyloid cardiomyopathy because they can worsen low blood pressure. Your cardiologist will need to carefully balance these competing priorities.
Kidney Involvement
When amyloid deposits accumulate in the kidneys, the most common early sign is protein spilling into the urine, sometimes in large amounts. This can lead to swelling in the legs and around the eyes. Treating the underlying amyloidosis is the primary strategy for preserving kidney function, but if damage progresses, dialysis or kidney transplantation may eventually become necessary. In AA amyloidosis, getting inflammation under control can actually reverse some kidney damage, making early and aggressive treatment especially important.
How Treatment Is Chosen
The first and most critical step is identifying exactly which type of amyloidosis you have. This typically requires a tissue biopsy (often from abdominal fat, bone marrow, or the affected organ) combined with specialized staining and mass spectrometry to identify the specific protein involved. Getting this right matters enormously, because treatments for one type can be useless or even harmful for another.
From there, treatment decisions depend on which organs are involved, how much damage has already occurred, and your overall fitness. Cardiac biomarkers and kidney function tests help doctors stage the disease and determine which therapies you can safely tolerate. For AL amyloidosis, the speed of response matters: the faster the abnormal protein levels drop, the better the chance that organ function stabilizes or improves. For ATTR amyloidosis, treatment is often long-term or lifelong, aimed at slowing a more gradual disease course. For AA amyloidosis, the focus shifts to the rheumatologist or specialist managing whatever inflammatory condition is driving it.
Treatment plans are highly individualized, and most patients with amyloidosis are best served at specialized amyloidosis centers where teams have experience across all subtypes. The landscape has changed dramatically in the past decade, with multiple new drug classes offering real improvements in quality of life and survival across all major forms of the disease.